Short description
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Description
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Last funding
Nopepepe
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
South San Francisco, California, United States, North America
Founded on
January 1, 2018
Exited on
June 16, 2021
Went public on
June 16, 2021
Stock symbol
LYEL
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$34056 - 789030
Sign in for full access
Investors
Cannot Access, No Way, Noaccessforu, No Way, Nopepepe
Sign in for full access
Founders
Rick Klausner, Scott Boyken
Funding rounds count
6
Portfolio organisations count
Nopepepe, Noaccessforu
Sign in for full access
Lead investments count
2
Exits count
Noaccess, Cannot Access
Sign in for full access
IPO exits count
1